Leadership Changes at Precision for Medicine
Precision for Medicine, a prominent operating unit of Precision Medicine Group, has made strategic leadership changes that underscore its commitment to driving innovation in drug development. Recently, the company announced the promotion of Sofia Baig to the role of President, Precision for Medicine, and the appointment of Daisy DeWeese-Gatt, MPH, as President of Clinical Solutions. These changes are set to enhance the company's efforts in providing cutting-edge services to biotechnology and pharmaceutical sectors.
Sofia Baig's Promotion: A Step Forward
Sofia Baig, who previously served as President of Clinical Solutions, takes on the expanded role of President at Precision for Medicine. With over 30 years in the pharmaceutical and clinical research services industry, Sofia's extensive knowledge and dedication have significantly contributed to the organization's success. During her tenure as President of Clinical Solutions, she played a pivotal role in optimizing business practices and streamlining operations.
Under her leadership, Precision for Medicine has integrated laboratory services with global contract research organization (CRO) services to provide exceptional value to clients. By combining Translational Sciences and Clinical Solutions, the company maximizes the potential for new treatments throughout all stages of development.
Chad Clark Acknowledges Sofia's Impact
Chad Clark, President and Chief Operating Officer of Precision Medicine Group, expressed his excitement regarding Sofia's well-deserved promotion. He emphasized her contributions over the past 15 years in scaling Precision for Medicine to meet the evolving needs of life sciences companies. Sofia's vision for expanding the company's services beyond current capabilities is a testament to her leadership skills.
Daisy DeWeese-Gatt Joins the Leadership Team
Alongside Sofia, Daisy DeWeese-Gatt has been appointed as President, Clinical Solutions. With a wealth of experience spanning over 25 years in global drug development, Daisy brings a much-needed expertise in oncology and rare diseases, which are vital therapeutic areas for Precision for Medicine. Her previous role as Senior Vice President at ICON has prepared her to lead teams across numerous countries effectively.
Daisy's proven ability to navigate complex projects and her history of fostering strong global teams will be instrumental as Precision for Medicine aims to broaden its impact in the industry. Her commitment to a people-first culture aligns perfectly with the company’s values and vision for growth.
Commitment to Excellence in Drug Development
Both leaders are set to implement strategies that prioritize rapid advancements in drug development timelines. With their combined insights, the organization is poised to enhance its contribution to the healthcare ecosystem, ensuring that innovative therapies reach patients efficiently. Their efforts will focus on integrating clinical phases with trial execution and scientific knowledge.
About Sofia Baig
Sofia Baig is well-respected in the pharmaceutical industry with a career that includes significant roles at leading organizations. Before joining Precision for Medicine, she made her mark at Parexel, where she globally expanded service lines and achieved impressive fiscal growth. Her academic credentials include a B.Sc. in Chemistry from the University of Birmingham in the UK.
About Daisy DeWeese-Gatt
Daisy DeWeese-Gatt has a distinguished background in clinical research with her previous position as Senior Vice President at ICON, managing large teams and extensive drug development operations. Her educational background includes a Master's in Public Health from Tulane University and a B.A. in Spanish from Davis and Elkins College. She also teaches part-time at the University of North Carolina, Wilmington, demonstrating her commitment to education and growth in the field.
About Precision for Medicine
Precision for Medicine stands out as the first biomarker-driven organization catering to the needs of life sciences companies. Through clinical research innovation, it integrates trial design with scientific expertise, thereby accelerating the research and approval processes. With 3,500 professionals across multiple continents, the organization continues to lead in global drug development efforts.
About Precision Medicine Group
Founded in 2012, Precision Medicine Group is dedicated to supporting enhanced approaches to pharmaceutical development. By offering a comprehensive framework, the company assists clients in navigating the complexities of drug commercialization in this evolving field. It has established a strong presence across North America, Europe, and Asia, with a commitment to fostering innovation in the healthcare sector.
Frequently Asked Questions
What has changed in leadership at Precision for Medicine?
Sofia Baig has been promoted to President, while Daisy DeWeese-Gatt has been appointed as President of Clinical Solutions.
What is Sofia Baig’s role in the company?
Sofia Baig oversees Translational Sciences and Clinical Solutions, ensuring effective drug development and integration of services to enhance client offerings.
What experience does Daisy DeWeese-Gatt bring to Precision for Medicine?
Daisy has over 25 years of experience in global drug development, specifically in oncology and rare diseases, and has led large international teams in her previous roles.
How does Precision for Medicine support drug development?
As a biomarker-driven organization, Precision for Medicine integrates clinical research with scientific expertise to accelerate the approval and availability of new treatments.
What is the mission of Precision Medicine Group?
Precision Medicine Group aims to provide specialized services that enhance drug development and commercialization, ensuring effective delivery of innovative medical solutions.
